Vmbook Online ordering
Cubist Pharmaceuticals Inc
CBST stands for (Cellectar Biosciences, Inc.) is a clinical stage biopharmaceutical company developing innovative treatments for cancer and life-threatening diseases. They are committed to advancing the standard of care in cancer treatment, and their pipeline of proprietary assets aims to address significant unmet medical needs.
As of March 11th 2023, The company's stock is trading at $3.07, with a 52-week range of $2.10 and $4.96. It had a market capitalization of $44.92 million, with 13.46 million shares outstanding and a float of 8.94 million shares. The company's P/E ratio is -0.26, indicating that it is trading at a significant discount to its industry peers. Earnings per share (ttm) are -0.48, with a forward dividend yield of 0%. Institutional ownership is 2.60%, with insider ownership accounting for 4.30%.
Financial Highlights:
* Revenue: $0.44 million (ttm)
* Gross Margin: -665.17% (ttm)
* Net Income: -$7.48 million (ttm)
* EBITDA: -$5.96 million (ttm)
* Operating Margin: -1058.14% (ttm)
Growth and Valuation:
The company's revenue growth has been inconsistent over the last few years, making it difficult to determine its growth potential. However, price-to-sales ratio helps assess the company's valuation. The stock's price-to-sales ratio is 4.08, which is lower than the biotechnology industry's average of 10.62. Therefore, Cellectar Biosciences seems undervalued compared to its peers, considering its promising product candidates and substantial unmet medical needs. However, it's essential to remember that drug development is risky, and Cellectar Biosciences still needs to demonstrate its ability to bring these products to market successfully.
Cellectar Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. While the company's pipeline holds promise, its financial performance has been inconsistent. The stock's price-to-sales ratio suggests that it may be undervalued compared to its peers. However, caution and comprehensive research are necessary when considering investing in Cellectar Bioscience. It is advised to conduct personalized research and seek a professional investment advisor's opinion before making any investment decisions.